Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$51.41 -3.7%	$48.19	$21.02 ▼ $58.40	$4.25B	-0.15	1.05 million shs	1.42 million shs
ARCT Arcturus Therapeutics	$12.99 -0.2%	$12.42	$8.04 ▼ $25.88	$352.84M	2.27	425,492 shs	489,341 shs
ENTA Enanta Pharmaceuticals	$7.70 +1.9%	$6.40	$4.09 ▼ $17.24	$161.61M	0.84	282,381 shs	135,156 shs
EPIX ESSA Pharma	$1.73 +1.8%	$1.71	$1.40 ▼ $7.88	$75.46M	1.56	339,262 shs	59,775 shs
PAHC Phibro Animal Health	$26.62 +4.2%	$22.99	$16.16 ▼ $26.77	$1.04B	0.75	211,856 shs	271,863 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	-3.65%	-4.66%	+0.76%	+22.55%	+121.98%
ARCT Arcturus Therapeutics	-0.15%	-3.13%	+2.85%	+27.35%	-45.10%
ENTA Enanta Pharmaceuticals	+1.85%	+5.19%	+28.98%	+45.28%	-41.09%
EPIX ESSA Pharma	+1.76%	0.00%	+2.98%	+9.49%	-66.21%
PAHC Phibro Animal Health	+4.23%	+7.47%	+8.30%	+21.55%	+56.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKRO Akero Therapeutics	3.5707 of 5 stars	3.5	1.0	0.0	4.7	2.0	0.8	0.0
ARCT Arcturus Therapeutics	3.7651 of 5 stars	4.6	2.0	0.0	0.0	3.4	2.5	0.6
ENTA Enanta Pharmaceuticals	4.0369 of 5 stars	3.4	2.0	0.0	4.7	2.3	2.5	0.0
EPIX ESSA Pharma	1.9655 of 5 stars	2.0	2.0	0.0	0.0	3.3	2.5	1.3
PAHC Phibro Animal Health	3.6413 of 5 stars	0.8	2.0	2.5	1.1	3.0	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	3.00	Buy	$82.50	60.47% Upside
ARCT Arcturus Therapeutics	3.11	Buy	$53.50	311.86% Upside
ENTA Enanta Pharmaceuticals	2.80	Moderate Buy	$18.00	133.77% Upside
EPIX ESSA Pharma	2.00	Hold	$2.00	15.61% Upside
PAHC Phibro Animal Health	1.67	Reduce	$21.80	-18.11% Downside

Current Analyst Ratings Breakdown

Latest ENTA, PAHC, ARCT, AKRO, and EPIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
6/3/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$23.00 ➝ $24.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/27/2025	AKRO Akero Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$63.00 ➝ $64.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	AKRO Akero Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $78.00
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
ARCT Arcturus Therapeutics	$152.31M	2.31	N/A	N/A	$8.90 per share	1.46
ENTA Enanta Pharmaceuticals	$67.64M	2.43	N/A	N/A	$6.08 per share	1.27
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$2.81 per share	N/A
PAHC Phibro Animal Health	$1.02B	1.06	$2.20 per share	12.08	$6.34 per share	4.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$252.06M	-$1.95	N/A	N/A	N/A	N/A	-15.19%	-13.97%	8/8/2025 (Estimated)
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/4/2025 (Estimated)
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.54	N/A	N/A	N/A	-149.57%	-79.83%	-26.65%	8/4/2025 (Estimated)
EPIX ESSA Pharma	-$28.54M	-$0.63	N/A	N/A	N/A	N/A	-23.48%	-22.86%	8/4/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	34.13	12.68	0.48	2.68%	30.51%	6.89%	8/27/2025 (Estimated)

Latest ENTA, PAHC, ARCT, AKRO, and EPIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/12/2025	Q2 2025	ENTA Enanta Pharmaceuticals	-$1.04	-$1.06	-$0.02	-$1.06	$15.96 million	$14.93 million
5/8/2025	Q2 2025	EPIX ESSA Pharma	-$0.19	-$0.14	+$0.05	-$0.14	N/A	N/A
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.80%	N/A	61.54%	N/A

Latest ENTA, PAHC, ARCT, AKRO, and EPIX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	0.03	16.80	16.80
ARCT Arcturus Therapeutics	0.06	5.64	5.64
ENTA Enanta Pharmaceuticals	N/A	5.29	5.29
EPIX ESSA Pharma	N/A	67.15	67.15
PAHC Phibro Animal Health	2.67	2.91	1.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
ARCT Arcturus Therapeutics	94.54%
ENTA Enanta Pharmaceuticals	94.99%
EPIX ESSA Pharma	75.12%
PAHC Phibro Animal Health	99.34%

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.07%
ARCT Arcturus Therapeutics	15.30%
ENTA Enanta Pharmaceuticals	13.89%
EPIX ESSA Pharma	15.50%
PAHC Phibro Animal Health	50.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	79.72 million	74.08 million	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.97 million	Optionable
ENTA Enanta Pharmaceuticals	160	21.38 million	18.41 million	Optionable
EPIX ESSA Pharma	50	44.39 million	37.51 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable

ENTA, PAHC, ARCT, AKRO, and EPIX Headlines

Recent News About These Companies

Phibro Animal Health Stock Up 52.8% in a Year: What's Driving the Rise?

July 1 at 9:15 AM | zacks.com

Phibro Animal Health (NASDAQ:PAHC) versus Metastat (OTCMKTS:MTST) Critical Comparison

July 1 at 4:33 AM | americanbankingnews.com

PAHC vs. BSX: Which Stock Is the Better Value Option?

June 30 at 12:41 PM | zacks.com

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

June 30 at 10:40 AM | zacks.com

Phibro Animal Health (NASDAQ:PAHC) PT Set at $26.00 by Morgan Stanley

June 27, 2025 | americanbankingnews.com

Morgan Stanley Raises Phibro Animal Health (NASDAQ:PAHC) Price Target to $26.00

June 25, 2025 | marketbeat.com

Investors in Phibro Animal Health (NASDAQ:PAHC) have seen decent returns of 45% over the past year

June 25, 2025 | finance.yahoo.com

Best Growth Stocks to Buy for June 25th

June 25, 2025 | zacks.com

Phibro Animal Health Corporation (PAHC) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Is Phibro (PAHC) a Solid Growth Stock? 3 Reasons to Think "Yes"

June 23, 2025 | zacks.com

Zacks Research Issues Optimistic Forecast for PAHC Earnings

June 19, 2025 | marketbeat.com

Reasons to Add PAHC Stock to Your Portfolio Right Now

June 18, 2025 | zacks.com

BNP Paribas Upgrades Phibro Animal Health (NASDAQ:PAHC) to "Hold"

June 18, 2025 | marketbeat.com

Sowell Financial Services LLC Takes $1.98 Million Position in Phibro Animal Health Corporation (NASDAQ:PAHC)

June 18, 2025 | marketbeat.com

GAMMA Investing LLC Has $784,000 Stock Position in Phibro Animal Health Corporation (NASDAQ:PAHC)

June 18, 2025 | marketbeat.com

Phibro Animal Health Co. (NASDAQ:PAHC) Given Consensus Recommendation of "Reduce" by Brokerages

June 16, 2025 | marketbeat.com

Phibro Animal Health (NASDAQ:PAHC) Upgraded at BNP Paribas Exane

June 16, 2025 | marketbeat.com

Harbor Capital Advisors Inc. Has $231,000 Holdings in Phibro Animal Health Co. (NASDAQ:PAHC)

June 15, 2025 | marketbeat.com

PAHC vs. BSX: Which Stock Should Value Investors Buy Now?

June 13, 2025 | zacks.com

4 Stocks Trading Near 52-Week High With More Upside Potential

June 13, 2025 | zacks.com

Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?

June 13, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
Super Micro Computer Stock's Rally Backed by Strong Financials
By Gabriel Osorio-Mazilli | June 19, 2025
View Super Micro Computer Stock's Rally Backed by Strong Financials
A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names
By Gabriel Osorio-Mazilli | June 6, 2025
View A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names
Snag These 3 Bargain Tech Stocks Before They Pop
By Gabriel Osorio-Mazilli | June 27, 2025
View Snag These 3 Bargain Tech Stocks Before They Pop

ENTA, PAHC, ARCT, AKRO, and EPIX Company Descriptions

Akero Therapeutics NASDAQ:AKRO

$51.41 -1.95 (-3.65%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$51.88 +0.47 (+0.90%)

As of 07/1/2025 07:55 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Arcturus Therapeutics NASDAQ:ARCT

$12.99 -0.02 (-0.15%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$13.25 +0.26 (+2.00%)

As of 07/1/2025 07:12 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Enanta Pharmaceuticals NASDAQ:ENTA

$7.70 +0.14 (+1.85%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$7.70 +0.00 (+0.06%)

As of 07/1/2025 04:04 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

ESSA Pharma NASDAQ:EPIX

$1.73 +0.03 (+1.76%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$1.72 0.00 (-0.29%)

As of 07/1/2025 05:05 PM Eastern

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Phibro Animal Health NASDAQ:PAHC

$26.62 +1.08 (+4.23%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$26.60 -0.02 (-0.06%)

As of 07/1/2025 04:04 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENTA, PAHC, ARCT, AKRO, and EPIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENTA, PAHC, ARCT, AKRO, and EPIX Earnings

Compare Dividends

Latest ENTA, PAHC, ARCT, AKRO, and EPIX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENTA, PAHC, ARCT, AKRO, and EPIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ENTA, PAHC, ARCT, AKRO, and EPIX Company Descriptions

Akero Therapeutics NASDAQ:AKRO

Arcturus Therapeutics NASDAQ:ARCT

Enanta Pharmaceuticals NASDAQ:ENTA

ESSA Pharma NASDAQ:EPIX

Phibro Animal Health NASDAQ:PAHC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools